Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 14, 2025 08:00 ET | Source: Tr1X, Inc.

Tr1X Announces FDA Clearance of IND Application for TRX319, a First-in-Class Allogeneic CAR-Tr1 Treg Cell Therapy for Progressive Multiple Sclerosis, and $50 Million in Additional Financing

Tr1X announced the FDA has cleared its IND application for TRX319 in progressive multiple sclerosis and a $50M financing that extends its runway into 2027.
September 24, 2025 08:30 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress

BOSTON, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
September 24, 2025 02:30 ET | Source: Novartis Pharma AG

New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies

ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis (RMS) following switch to Kesimpta after...
August 19, 2025 10:59 ET | Source: Spherix Global Insights

Spherix Global Insights Announces Upcoming New Special Topix™ Unpacking Payer Management Strategies Across Over 25 Therapeutic Areas

EXTON, PA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Spherix Global Insights announces the upcoming release of its latest Special Topix™ service, Payer Management Strategies, providing pharmaceutical...
June 24, 2025 13:00 ET | Source: DelveInsight Business Research LLP

Multiple Sclerosis Clinical Trial Pipeline Shows Potential with Active Contributions from 60+ Key Companies | DelveInsight

New York, USA, June 24, 2025 (GLOBE NEWSWIRE) -- Multiple Sclerosis Clinical Trial Pipeline Shows Potential with Active Contributions from 60+ Key Companies | DelveInsight Multiple Sclerosis, the...
June 13, 2025 10:30 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
May 08, 2025 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

Autolus announces its operational and financial results for the first quarter ended March 31, 2025.
May 06, 2025 07:00 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis

Meaningful Fatigue score reduction seen in study is a critically important quality of life (QoL) measure for Multiple Sclerosis patients.All patients experienced stabilization of Expanded Disability...
April 23, 2025 16:05 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event

Autolus presented updates on its development pipeline and plans for expansion in autoimmune diseases at an R&D investor event.
April 23, 2025 07:00 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial

NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...